STAAR Surgical (STAA) said Monday that shareholder Broadwood Partners recycled allegedly "flawed, misleading, and misinformed" claims in its Friday presentation urging stockholders to reject the proposed takeover by Alcon (ALC).

Broadwood's analysis does not reflect STAAR's "actual performance today or reasonable expectations going forward," the company said.

STAAR said it had refuted Broadwood's claims in detail in its investor materials and related presentation on Sept. 26.

The company said it believes Broadwood's perspective is not shared by the majority of its stockholders and that its board continues to urge all shareholders to vote in favor of the proposed takeover by Alcon.

Broadwood, in a letter issued to the STAAR board Monday, said there is no justification for the board's decision to sell the company for $28 per share after rejecting Alcon's offer last year for $58 per share.

Broadwood said it owns 27.5% of STAAR's common shares.

STAAR said it is set to hold a virtual special stockholders' meeting on Oct. 23 to vote on the proposed Alcon merger.